Analyst Ratings for Prime Medicine (PRME)
PRME Rating Summary
PRME Price Target Summary
- Highest: $10.00 (Chardan)
- Lowest: $4.25 (Citi)
- Average: $6.25
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$6.25 (+55.9%)
* Over Last 12-Mos
Rating Score: 6 / 10
Percentile Rank: 64%
Avg. $ Target:
$6.25 (+55.9%)
* Over Last 12-Mos
Rating Score: 6 / 10
Percentile Rank: 64%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/23/2025 | LifeSci Capital | N/A | New Coverage | Outperform (N/A) |
6.00 (N/A) |
3.70 (4.01) |
8.38% | Details |
| 5/27/2025 | Citi » Updated 11/11/2025 |
Samantha Semenkow | Downgrade | Neutral (Buy) |
4.25 (5.00) |
1.23 (4.01) |
226.02% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
